felbamate and Nausea
felbamate has been researched along with Nausea in 4 studies
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined." | 7.69 | Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996) |
| "Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs." | 6.68 | Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997) |
| "After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy." | 4.79 | Felbamate. ( Leppik, IE, 1995) |
| "The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined." | 3.69 | Felbamate levels in patients with epilepsy. ( Harden, CL; Kutt, H; Trifiletti, R, 1996) |
| "Felbamate (FBM) pharmacokinetic parameters, safety and tolerability in the dose range of 1,200-6,000 mg/day were assessed in two open-label studies with similar designs." | 2.68 | Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. ( Lyness, WH; Narang-Sachdeo, SK; Perhach, JL; Rosenberg, A; Sachdeo, R; Shumaker, RC, 1997) |
| "Felbamate (FBM) was the first of the new antiepileptic drugs (AEDs) approved in the United States in 1993 with broad-spectrum efficacy against partial and generalized seizures of various types, and indicated for use as adjunctive and monotherapy." | 2.40 | Felbamate. ( Pellock, JM, 1999) |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Harden, CL | 1 |
| Trifiletti, R | 1 |
| Kutt, H | 1 |
| Leppik, IE | 1 |
| Sachdeo, R | 1 |
| Narang-Sachdeo, SK | 1 |
| Shumaker, RC | 1 |
| Perhach, JL | 1 |
| Lyness, WH | 1 |
| Rosenberg, A | 1 |
| Pellock, JM | 1 |
Reviews
2 reviews available for felbamate and Nausea
| Article | Year |
|---|---|
Felbamate.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Interact | 1995 |
Felbamate.
Topics: Adult; Age Factors; Anemia, Aplastic; Anorexia; Anticonvulsants; Child; Drug Administration Schedule | 1999 |
Trials
1 trial available for felbamate and Nausea
| Article | Year |
|---|---|
Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
Topics: Adolescent; Adult; Anorexia; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Dr | 1997 |
Other Studies
1 other study available for felbamate and Nausea
| Article | Year |
|---|---|
Felbamate levels in patients with epilepsy.
Topics: Adolescent; Anorexia; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid | 1996 |